By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Presidio Pharmaceuticals, Inc. 

1700 Owens Street
Suite 585
San Francisco  California  94158  U.S.A.
Phone: 415-655-7560 Fax: 415-986-2864


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Presidio Pharmaceuticals, Inc. Announces a High Rate of Virologic Response in an Ongoing Phase 2 Hepatitis C Trial of a New All-Oral Combination of Presidio's PPI-668 With Boehringer Ingelheim Corporation's Faldaprevir and Deleobuvir 11/4/2013 11:23:22 AM
Boehringer Ingelheim Corporation Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals, Inc. Clinical Collaboration 9/10/2013 9:22:33 AM
Boehringer Ingelheim Corporation Forms JV With Presidio Pharmaceuticals, Inc. 3/13/2013 7:05:44 AM
Biocryst Pharmaceuticals (BCRX), Presidio Pharmaceuticals, Inc. Call Off Proposed $101 Million Acquisition 11/30/2012 7:54:26 AM
Biocryst Pharmaceuticals (BCRX) Snags Presidio Pharmaceuticals, Inc. for $101 Million 10/18/2012 6:54:12 AM
Presidio Pharmaceuticals, Inc. Successfully Completes Phase 1 Proof-of-Concept for PPI-668, its Potent HCV NS5A Inhibitor, in Hepatitis C Patients With Genotype-1 Infection 6/26/2012 10:59:10 AM
Presidio Pharmaceuticals, Inc. Announces a New Clinical Candidate, PPI-383, a Novel Pan-Genotypic Non-Nucleoside Polymerase Inhibitor for HCV 4/23/2012 10:23:50 AM
Presidio Pharmaceuticals, Inc. Announces Phase 1a-1b Clinical Results with PPI-668, a Potent Pan-genotypic HCV NS5A Inhibitor 4/18/2012 10:47:29 PM
Presidio Pharmaceuticals, Inc. Reports Progress with Hepatitis C Antiviral Programs 1/9/2012 6:15:48 AM
Presidio Pharmaceuticals, Inc. Announces Clinical Proof-of-Concept Data for its First HCV NS5A Inhibitor, PPI-461, and Initiation of Clinical Testing for its Second-Generation NS5A Inhibitor, PPI-668 11/4/2011 6:40:08 AM
12345
//-->